Literature DB >> 7759716

Lack of association between the insertion/deletion polymorphism of the angiotensin-converting enzyme gene and idiopathic dilated cardiomyopathy.

H E Montgomery1, P J Keeling, J H Goldman, S E Humphries, P J Talmud, W J McKenna.   

Abstract

OBJECTIVES: We sought to investigate the role of polymorphisms of the gene for angiotensin-converting enzyme in the development and progression of idiopathic dilated cardiomyopathy.
BACKGROUND: Cardiovascular renin-angiotensin systems may be involved in cardiac remodeling and fibrosis. The absence (deletion [D]) of a 287-base pair marker in the angiotensin-converting enzyme gene (introm 16) is associated with increased serum angiotensin-converting enzyme levels. The DD genotype may be a risk factor for the development of end-stage heart failure due to cardiomyopathy. We therefore examined the relation of the angiotensin-converting enzyme genotype to idiopathic dilated cardiomyopathy and to markers of disease severity.
METHODS: We studied 364 control subjects and 99 consecutive patients with idiopathic dilated cardiomyopathy. When the incidence of the DD genotype in our control group was assumed to be similar to that previously reported (27%), this study had a power of 0.9 to detect a different incidence in the patient group, if the true incidence in patients was 42%. Deoxyribonucleic acid (DNA) was isolated from blood samples, and angiotensin-converting enzyme genotype was determined by specific polymerase chain reaction and separation of amplified fragments by agarose gel electrophoresis. We also compared genotype distribution with that in previously reported European control subjects. Functional status, clinical course over a mean +/- SD of 28 +/- 33 months and outcome were documented. Cardiac morphology and function and evidence of rhythm disturbance were noninvasively determined.
RESULTS: Angiotensin-converting enzyme genotype distribution and allele frequencies were similar in patients and control subjects to within 10% (with 95% confidence) and were also similar between patients and European control subjects. No markers of disease severity or progression other than duration of symptoms before diagnosis and the number of ventricular ectopic beats/h were significantly associated with the presence of the DD alleles.
CONCLUSIONS: We find no evidence to support an association between angiotensin-converting enzyme genotype and either the diagnosis of idiopathic dilated cardiomyopathy itself or progression of the disease.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7759716     DOI: 10.1016/0735-1097(95)00109-h

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  13 in total

1.  RAAS and adrenergic genes in heart failure: Function, predisposition and survival implications.

Authors:  Alberto J Alves; Nir Eynon; José Oliveira; Ehud Goldhammer
Journal:  World J Cardiol       Date:  2010-07-26

2.  Association of angiotensin-converting enzyme I/D polymorphism with heart failure: a meta-analysis.

Authors:  Yuanyuan Bai; Liang Wang; Shengshou Hu; Yingjie Wei
Journal:  Mol Cell Biochem       Date:  2011-10-21       Impact factor: 3.396

Review 3.  Cardiovascular disease and genetics of the renin-angiotensin system.

Authors:  S B Harrap
Journal:  Heart       Date:  1996-11       Impact factor: 5.994

Review 4.  The genomic architecture of sporadic heart failure.

Authors:  Gerald W Dorn
Journal:  Circ Res       Date:  2011-05-13       Impact factor: 17.367

Review 5.  Angiotensin converting enzyme gene insertion/deletion polymorphism and cardiovascular disease: therapeutic implications.

Authors:  Tianhua Niu; Xiu Chen; Xiping Xu
Journal:  Drugs       Date:  2002       Impact factor: 9.546

6.  Genetic variants are not associated with outcome in patients with coronary artery disease and left ventricular dysfunction: results of the Genetic Substudy of the Surgical Treatment for Ischemic Heart Failure (STICH) trials.

Authors:  Arthur M Feldman; Lilin She; Dennis M McNamara; Douglas L Mann; Michael R Bristow; Alan S Maisel; Daniel R Wagner; Bert Andersson; Luigi Chiariello; Christopher S Hayward; Paul Hendry; John D Parker; Normand Racine; Craig H Selzman; Michele Senni; Janina Stepinska; Marian Zembala; Jean Rouleau; Eric J Velazquez; Kerry L Lee
Journal:  Cardiology       Date:  2015-01-13       Impact factor: 1.869

Review 7.  Pharmacogenetics of heart failure: evidence, opportunities, and challenges for cardiovascular pharmacogenomics.

Authors:  Matthew T Wheeler; Michael Ho; Joshua W Knowles; Aleks Pavlovic; Euan A Ashley
Journal:  J Cardiovasc Transl Res       Date:  2008-01-29       Impact factor: 4.132

8.  Ten renin-angiotensin system-related gene polymorphisms in maximally treated Canadian Caucasian patients with heart failure.

Authors:  Marcin Zakrzewski-Jakubiak; Simon de Denus; Marie-Pierre Dubé; François Bélanger; Michel White; Jacques Turgeon
Journal:  Br J Clin Pharmacol       Date:  2008-02-12       Impact factor: 4.335

9.  Does angiotensin-converting enzyme polymorphism have association with symptomatic benign prostatic hyperplasia?

Authors:  Hemant Kumar Bid; Parmeet Kaur Manchanda; Rituraj Konwar; Kasif Hanif; V Laxman Nayak; Vishwajeet Singh
Journal:  Indian J Urol       Date:  2010-10

10.  Impact of angiotensin I converting enzyme insertion/deletion polymorphisms on dilated cardiomyopathy and hypertrophic cardiomyopathy risk.

Authors:  Jianmin Yang; Yunhan Zhao; Panpan Hao; Xiao Meng; Mei Dong; Ying Wang; Yun Zhang; Cheng Zhang
Journal:  PLoS One       Date:  2013-05-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.